Observational and retrospective study on the effect and safety of Tumor Treating Fields for newly diagnosed glioblastoma

Observational and retrospective study on the effect and safety of Tumor Treating Fields for newly diagnosed glioblastoma - Observational and retrospective study on the effect and safety of Tumor Treating Fields for newly diagnosed glioblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041745

Enrollment

460

Registered

2020-10-01

Start date

2023-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Newly diagnosed glioblastoma 2) Age 18y.o.- 80 y.o. 3) Male and female 4) KPS 70-100 5) Patient who received concomitant RT/Temozolomide 6) include the patients who was treated by carmustine wafers and photodynamic therapy

Exclusion criteria

Exclusion criteria: 1) Lesion was mainly located at cerebellum or brainstem 2) Patient with leptomeningeal dissemination 3) Patient with progressive disease during concomitant RT/Temozolomide 4) Patient who received bevacizumab

Design outcomes

Primary

Measure	Time frame
Overall survival rate	—

Secondary

Measure	Time frame
Overall survival rate of the subgroup classified by extent of resection, KPS, age, and implantation of BCNU wafers Adverse effect	—

Countries

Japan

Contacts

Public ContactMasayuki Kanamori

Tohoku University Hospital Department of Neurosurgery

mkanamori@med.tohoku.ac.jp0227177230

Outcome results